Harpreet Singh, Immatics CEO
September 16, 2024 09:07 AM EDT
Deals
R&D

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

Kyle LaHucik

Senior Reporter

BARCELONA — Im­mat­ics pre­sent­ed more clin­i­cal da­ta on its bis­pe­cif­ic T cell en­gager at Eu­rope’s largest can­cer con­fer­ence.

But the Ger­man …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times